CA
COGT icon

Clearstead Advisors’s Cogent Biosciences COGT Stock Holding History

Clearstead Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$36 – 2372
2025
Q4 		$36 Sell
1
-2
-67% -$56 ﹤0.01% 2641
2025
Q3 		$44 Buy
+3
New +$36 ﹤0.01% 2982

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Clearstead Advisors's COGT Position: Q1 2026 in Review

Clearstead Advisors sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 1 share — an estimated $36 sold.

Clearstead Advisors first reported a position in COGT in Q3 2025 and held it in 2 quarters. The position peaked at $44 in Q3 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Clearstead Advisors reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Clearstead Advisors sold 1 Cogent Biosciences share in Q1 2026, an estimated $36.
  • Clearstead Advisors first reported a position in Cogent Biosciences in Q3 2025 and held it in 2 quarters.
  • Clearstead Advisors's Cogent Biosciences position peaked at $44 in Q3 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.